PepChile

Fertilidad Femenina y Optimización de Calidad de Óvulo

Categorías: Optimización Hormonal, Salud Femenina, Salud Reproductiva

Infertilidad femenina (baja reserva ovárica, mala calidad óvulo, ciclos irregulares) causada envejecimiento, estrés oxidativo mitocondrial óvulo, deficiencia hormonal (FSH, LH, estrogénica). Péptidos restauran eje HPG, amplificam GH/IGF-1 (folículo growth), reducen estrés oxidativo oocito, mejoran energía mitocondrial crucial para meiosis y desarrollo embrionario.

Resumen Simplificado

Kisspeptina 100-200mcg nightly (restaura pulsatilidad GnRH, FSH/LH optimization). GHRP-6 100-200mcg 2-3x/día (amplifica IGF-1, critical folículo growth señalización). GHK-Cu 1-2mg nightly (antioxidant oocito, mitochondrial protection). CoQ10 600-800mg daily (mitochondrial energy, fertilidad female potent). Timeline: ciclo regularization 1-2 ciclos, folículo quality 2-3 ciclos, óvulo viability improvement 3-6 meses (multiple ciclos necesarios assess improvement).

Kisspeptina, FSH, y Selección Folicular Ovárica

OOGENESIS & FOLLICULOGENESIS: ovario contiene finite pool óvulos (depósito max at birth 6-7 million, decline 1 million by age 30, 300k by menopause). Cada ciclo: FSH rise (days 1-5) stimula follicle growth (antral follicles 2-5mm → dominant follicle 18-22mm). FSH surge sustain LH spike trigger ovulación. KISSPEPTINA LOW AGING: GnRH pulsatilidad reduce → FSH responsiveness decline → follicle recruitment diminish, fewer óvulos desarrollan per ciclo (infertilidad primary mechanism aging female). KISSPEPTINA 100-200mcg NIGHTLY: (1) restore GnRH pulsatilidad; (2) FSH amplification; (3) follicle recruitment enhance—more antral follicles grow per ciclo. EFECT TIMING: semana 1-2 ciclo regularity initial improvement (menstruación más consistent). Ciclo 1-2: FSH levels optimization (measured day 3, should decrease <10 mIU/mL jika elevated). Ciclo 2-3: follicle number aumento observable ultrasound (AFC antral follicle count increase 20-40%). RESERVA OVÁRICA MEJORÍA: implied by AFC increase (although Kisspeptina no aumenta óvulos total—finite—pero optimize recruitment). OOCYTE MATURATION: FSH optimization → meiosis I completion (germinal vesicle breakdown), preparation MII arrest. Synchronized FSH signaling critical oocyte nuclear maturation.

IGF-1 Signaling: Folículo Growth dan Steroidogenesis

FOLÍCULO GROWTH ENDOCRINOLOGÍA: granulosa cells (folículo wall) secrete inhibin, activin, AMH. Theca cells secrete androgén precursores (aromatized estrogén by granulosa aromatase). Growth regulation: FSH + LOCAL IGF-1 signaling essential. IGF-1 receptor expression follicle increases con FSH stimulation. IGF-1 FUNCTION: (1) FSH amplification (paracrine signaling); (2) aromatase induction → androgén conversion estrogén; (3) inhibin secretion → FSH feedback. GHRP-6 & CJC-1295 (GH secretagogues): anterior pituitary GH release → hepatic IGF-1 production + local ovarian IGF-1 expression (ovary IGF-1 producing tissue). DOSIS GHRP-6: 100-200mcg 2-3x/día (morning + evening peak GH secretion windows). CJC-1295: 500-1000mcg IM every 7 días (synergy GHRP-6 amplification). EFEKTIVITAS: Ovarian IGF-1 levels increase folicular fluid (measured FSH stimulation assay), follicle growth rate enhanced 15-25%, steroid hormone (estradiol) production per follicle increased. TIMELINE EFFECT: GH secretion rapid (within days). IGF-1 hepatic accumulation 3-5 minggu. Folículo tissue remodeling (granulosa IGF-1 receptor sensitization) 1-2 ciclos. Maximum effect 2-3 ciclos (follicle numbers stabilize at optimized level).

Mitochondrial Energy dan Oocyte Viability

OOCYTE ENERGETICS: óvulo contiene 100,000-200,000 mitochondrias (terkait egg quality directly). Mitochondrial dysfunction → ATP depletion → impaired meiosis completion, anaphase lag (cromosoma nondisjunction), aneuploidía (cromosoma abnormality). Aging oocytes: mitochondrial DNA mutations, oxidative stress accumulation → energy crisis. MTDNA MUTATIONS aumenta con age (especially women >35 años—'maternal age effect' driven partly mitochondrial decline). GHK-Cu PEPTIDE: mitochondrial antioxidant, upregulate antioxidant enzymes, reduce ROS, preserve mtDNA integrity. MEKANISME GHK-Cu: (1) superoxide dismutase (SOD), catalase activation; (2) mitochondrial membrane potential preservation; (3) autophagy promotion—mitochondrial quality control; (4) reduce lipid peroxidation oocyte cytoplasm. DOSIS GHK-Cu: 1-2mg nightly (prefer systemic—subcutaneous—untuk oocyte penetrasi). CoQ10 COMPLEMENTARY: ubiquinone (mitochondrial electron transport complex I-III). CoQ10 600-800mg daily SUPERIOR female fertility studies (vs. 200mg for male). NAC (N-acetylcysteine) 1200-2400mg daily: glutathione synthesis, powerful oocyte antioxidant. TIMELINE MITOCHONDRIAL IMPROVEMENT: GHK-Cu + CoQ10 antioxidant immediate effect (ROS reduction 24-48 horas). mtDNA damage reversal slower (2-3 minggu cellular protection accumulation). Oocyte quality parameters (apoptosis markers, energy status) improvement 1-3 ciclos.

Comprehensive Female Fertility Protocol

INTEGRATED APPROACH: Kisspeptina (HPG axis) + GHRP-6/CJC-1295 (IGF-1 signaling) + GHK-Cu (antioxidant) + CoQ10 + NAC (mitochondrial support) + micronutrients (zinc, selenium, vitamin E, folate). BASELINE ASSESSMENT: FSH (day 3), estradiol, AMH (antimüllerian hormone—ovarian reserve marker), AFC ultrasound, comprehensive metabolic panel. PROTOCOL DOSING: Kisspeptina 100-200mcg nightly; GHRP-6 100mcg 2-3x/día or CJC-1295 500-1000mcg weekly; GHK-Cu 1-2mg nightly; CoQ10 600-800mg daily (ubiquinone form); NAC 1200-2400mg daily divided doses; zinc 25-30mg, selenium 100-200mcg, vitamin E 400 IU, folate 800mcg (methylfolate preferred). TIMELINE COMPREHENSIVE: Ciclo 1: hormonal stabilization, antioxidant accumulation. Ciclo 2: folículo growth optimization observable, cycle regularization. Ciclo 3: oocyte quality improvement (indirect—fewer aneuploidy if PGS tested). SUCCESSFUL OUTCOME METRICS: (1) FSH <10 mIU/mL; (2) AFC increase 20-40% (if low baseline); (3) Estradiol levels optimized (follicular phase 40-100 pg/mL); (4) Cycle regularity (±2 días variance); (5) Pregnancy achieved jika TTC (trying to conceive), or improved fertilization/embryo quality jika IVF. LIFESTYLE INTEGRATION: reduce stress (cortisol suppress FSH), quality sleep 7-8 horas, exercise moderate (excess exercise impair ovulation), minimize toxin exposure, optimize weight (BMI 18.5-24.9 ideal).

Hallazgos Clave

Productos relacionados

Más artículos en Optimización Hormonal

Más artículos en Salud Femenina

Preguntas frecuentes

¿Pueden péptidos restaurar reserva ovárica baja (AMH bajo)?
Parcialmente. Péptidos NO crean nuevos óvulos (cantidad finita genéticamente determinada). Pero optimize recruitment óvulos existentes—AFC puede aumentar 20-40% si baseline underutilization. Si AMH <1.0 ng/mL severa deficiency: Kisspeptina + GHRP-6 puede modest improvement (esperanza 15-25% AFC aumento maximum), pero reserva fundamental limitation remains. Más efectivo jif AMH 1.5-5.0 rango—moderate deficiency where optimization yields meaningful gains.
¿A qué edad es menos efectivo protocolo peptido fertilidad femenina?
Efficacy decline significant después edad 38-40 años (aneuploidy rate sube exponentially—80% aneuploidy by age 42+, genetic limite). Péptidos pueden optimize mitochondrial energy + FSH signaling, pero NO revert aneuploidy fundamentally. Mujeres <35: excellent efficacy (mitochondrial function intact). 35-38: buena efficacy (marginal aneuploidy increase). >38: modest efficacy—optimization worthwhile, pero genetic limits acknowledge. IVF + PGS testing pueden help jif edad avanzada (select euploid embryos).
¿Puedo usar protocolo durante IVF ciclo o debe preparación previa?
Mejor: 2-3 ciclos PREVIA IVF cycle (optimized baseline). Ciclo durante IVF possible pero suboptimal (timing de estimulación hormonal ovarian puede interfere peptido protocol titration). Recomendación: iniciar Kisspeptina + GHRP-6 + antioxidants 2-3 meses before IVF trigger, permitit folliculogenesis cycles optimization, luego IVF ciclo benefit from improved baseline oocyte quality. Si IVF urgente, begin peptido protocol durante down-regulation/baseline stage (before GnRH agonist stim), aunque less ideal.

Volver a la biblioteca de investigación